DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. About Trinity Biotech LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trini ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bios ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bio ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Eric Ri ...

Core Insights - Trinity Biotech plc is on track to achieve approximately $20 million of annualized run-rate EBITDASO on annualized revenues of approximately $75 million by Q2 2025, driven by growth in existing businesses and operational efficiencies [1][2] - The company reported a strong sequential growth of 39% quarter-on-quarter in Point-of-Care revenues, primarily due to the successful rollout of TrinScreen HIV test production [1][2] - Operational efficiencies have led to a 3.6 percentage point increase in gross margin percentage quarter-on-quarter, with further improvements expected through 2024 and into early 2025 [1][2] Business Performance - Total revenues for Q1 2024 were $14.7 million, a slight decrease of 0.8% compared to $14.8 million in Q1 2023 [4][29] - The Point-of-Care portfolio generated revenues of $3.0 million for Q1 2024, reflecting a 38.5% increase from $2.2 million in Q1 2023 [4][6] - TrinScreen HIV sales reached $1.2 million in Q1 2024, with total orders for 2024 supply amounting to $6 million [2][4] Profitability Improvements - The net loss decreased from $5.5 million in Q4 2023 to $3.3 million in Q1 2024, marking a 40% improvement [2][12] - EBITDASO improved by 62% compared to Q4 2023, with expectations for further improvements through 2024 [2][12] - Selling, general and administrative expenses decreased to $7.5 million in Q1 2024 from $8.6 million in Q1 2023, driven by cost-saving initiatives [10][11] Operational Initiatives - The company is implementing a comprehensive transformation plan that includes optimizing supply chains and centralizing corporate services [3][5] - Significant progress has been made in offshoring manufacturing activities, with plans to cease main manufacturing at the Kansas City plant by the end of 2024 [5] - The company has engaged a consultancy for the design of its next-generation Continuous Glucose Monitoring system and is progressing towards a pre-pivotal clinical trial [5] Financial Position - Cash balance increased from $3.7 million at the end of Q4 2023 to $5.8 million at the end of Q1 2024 [19] - The company incurred investing cash outflows of $14.0 million in Q1 2024, primarily related to the acquisition of Waveform assets [19][31] - The renegotiation of the term loan resulted in a reduction of net financial expenses from $2.4 million in Q1 2023 to $0.2 million in Q1 2024 [12][14] Market Compliance - The company received a deficiency letter from Nasdaq regarding the market value of publicly held shares falling below the minimum requirement [21] - A staff determination letter indicated that the company did not regain compliance by the deadline, but it intends to request a hearing to avoid delisting [22][23]

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information | Date: | Thursday, May 23, 2024 | | --- | --- | | Time: | 8:30 AM ET | | United States: | 1-877-407-0784 | | International: | 1- ...

Group 1 - Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors [3] - The company will report its financial results for the first quarter of 2024 on May 23, 2024, at 8:30 AM ET [1] - Trinity Biotech has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc., aiming to develop a range of biosensor devices starting with a continuous glucose monitoring product [3] Group 2 - The company's diagnostic systems include reagents and instrumentation for point-of-care and clinical laboratory segments, used to detect infectious diseases and quantify Haemoglobin A1c levels [3] - Trinity Biotech sells its products directly in the United States, Germany, France, and the U.K., and through a network of international distributors and strategic partners in over 75 countries worldwide [3]

OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Waveform Technologies, Inc. Statement of Assets Acquired and Liabilities Assumed Table of Contents Independent Auditors' Report To the Board of Trinity Biotech Plc Emphasis of matter | | Page No. | | --- | --- | | Independent Auditors' Report | 1 | | Statement of Assets Acquired and Liabilities Assumed as of January 30, 2024 | 2 | | Notes to Statement of Assets Acquired and Liabilities Assumed | 3 - 9 | Opinion We have audited the accompanying Statement of assets acquired and liabilities assume ...

Financial Data and Key Metrics Changes - Revenue for Q4 2023 was $13.4 million, down from $15.7 million in Q4 2022, a decline of $2.3 million driven by decreases in the hemoglobins business and point-of-care business [66] - Gross profit for the quarter was $4.6 million, representing a gross margin percentage of 34%, consistent with Q4 2022 [75] - SG&A expenses were $6.9 million, down from $9.7 million in Q4 2022, primarily due to lower share-based payments [76] - Operating loss for the quarter was $3.8 million, improved from $8.2 million in Q4 2022, attributed to lower impairment charges and SG&A expenses [70] Business Line Data and Key Metrics Changes - Hemoglobins business saw a decline of $1 million quarter-on-quarter due to deferred year-end shipments [66] - Point-of-care business experienced a decline of $0.5 million, partially offset by $0.4 million revenue from the TrinScreen test [67] - The autoimmune business declined by $0.6 million due to ceasing transplant testing activity [74] Market Data and Key Metrics Changes - The company expects growth in the international markets, particularly in Asia and Africa, rather than in the U.S. and Western Europe [17] - The TrinScreen product has begun generating revenue in Africa, with expectations for it to be a key growth driver [75] Company Strategy and Development Direction - The company is targeting approximately $20 million of annualized run-rate EBITDASO by Q2 2025, based on targeted annualized run-rate revenues of approximately $75 million [34] - A comprehensive transformation plan is in place to improve financial performance by reducing complexity and costs through consolidation and outsourcing [42][45] - The company aims to build a global business in wearable biosensors, focusing on continuous glucose monitors (CGMs) as a key growth driver [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong start to 2024, with expectations for revenue growth in Q1 2024 compared to Q4 2023 [35] - The management team is focused on executing initiatives to improve cash generation and reduce costs, with a strong emphasis on operational efficiency [10][44] - The company is optimistic about the CGM market, recognizing strong demand for lower-cost solutions [21] Other Important Information - The company entered into an amended credit agreement providing an additional $22 million in funding, with $12.5 million used for the acquisition of Waveform assets [71] - The amended term loan reduced the annual interest rate and early repayment penalties, maturing in January 2026 [82] Q&A Session Summary Question: What is the target gross margin for 2025? - Management targets a gross margin of around 50% through procurement efficiencies and outsourcing [7] Question: Is the growth expected to be evenly distributed between point-of-care and lab business? - Growth is expected to be more weighted towards point-of-care, particularly with the new TrinScreen product [11] Question: Will the EBITDA guidance include spending on the CGM segment? - The CGM spending is capitalized under IFRS and will only continue if it shows results [20] Question: Are the new diabetes products approved and ready for market? - The new products are effectively variants of existing approved products, with local registrations required in some markets [97] Question: When can the company expect to start generating revenue from CGM? - Clinical trials for the next-generation device are expected to begin in summer 2025, with market entry anticipated six months after that [110]